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Summary 
Synucleins are small, soluble proteins expressed primarily in neural tissue and in certain tumors. The
family includes three known proteins: -synuclein, -synuclein, and -synuclein. All synucleins have in
common a highly conserved -helical lipid-binding motif with similarity to the class-A2 lipid-binding
domains of the exchangeable apolipoproteins. Synuclein family members are not found outside
vertebrates, although they have some conserved structural similarity with plant ‘late-embryo-
abundant’ proteins. The - and -synuclein proteins are found primarily in brain tissue, where they are
seen mainly in presynaptic terminals. The -synuclein protein is found primarily in the peripheral
nervous system and retina, but its expression in breast tumors is a marker for tumor progression.
Normal cellular functions have not been determined for any of the synuclein proteins, although some
data suggest a role in the regulation of membrane stability and/or turnover. Mutations in -synuclein
are associated with rare familial cases of early-onset Parkinson’s disease, and the protein accumulates
abnormally in Parkinson’s disease, Alzheimer’s disease, and several other neurodegenerative illnesses.
The current challenge is to understand the normal cellular function of these proteins and how they
might contribute to the development of human disease.
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Gene organization and evolutionary history 
The synuclein family consists of three distinct genes, -synu-
clein, -synuclein, and -synuclein, which have so far been
described only in vertebrates. Table 1 catalogs the unique
members of the synuclein family that are currently listed in
GenBank [1]; these 16 sequences encode the orthologs of each
of the three synucleins in the species in which they have been
described. The sequences are shown aligned in Figure 1a and
their estimated relationships are indicated by the dendro-
gram in Figure 1b. The -synuclein gene has been mapped to
human chromosome 4q21.3-q22 [2], -synuclein to human
chromosome 5q35 [3], and -synuclein to human chromo-
some 10q23.2-q23.3 [4]. The -synuclein gene is organized
as 7 exons, 5 of which are protein-coding, while the -synu-
clein gene has 6 exons (5 protein-coding) and the -synuclein
gene has 5 exons (all protein-coding) (reviewed in [5]).
Characteristic structural features
All synuclein protein sequences consist of a highly conserved
amino-terminal domain that includes a variable number of
11-residue repeats and a less-conserved carboxy-terminal
domain that includes a preponderance of acidic residues.
The only significant divergences within the repeat domain
are the deletion of 11 amino acids (residues 53-63) in all
-synucleins and the addition of a repeat after residue 32 in
the -synuclein of the electric ray Torpedo californica
(Figure 1a). The 11-mer repeats make up a conserved
apolipoprotein-like class-A2 helix (Figure 2a,b), which medi-
ates binding to phospholipid vesicles; lipid binding is accom-
panied by a large shift in protein secondary structure, from
around 3% to over 70% -helix [6]. 
Although no confirmed synuclein orthologs have been iden-
tified in non-vertebrates, a low-scoring BLAST ‘hit’ for simi-
larity is obtained for LEA76, a plant protein belonging to the
late embryo-abundant (LEA) group III protein family. Upon
further examination, the sequence similarity is attributable
to the presence of an 11-residue repeat encoding a similar
class-A2 lipid-binding motif (Figure 2c). Like synucleins,
LEA group III proteins are relatively unordered in solution;
upon fast drying, however, they shift to a largely -helical
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conformation [7], and are hypothesized to associate with and
stabilize cellular membranes against desiccation stress. A
Caenorhabditis elegans LEA homolog has been reported [8]
that also shares this structural motif (Figure 2d). Thus,
despite the low degree of primary sequence similarity,
further scrutiny of the LEA proteins’ potential functional
relationships to the synucleins is warranted.
Localization and function
The first synuclein was identified in 1988 by Maroteaux et al.
[9], who screened an expression library with an antiserum
raised against purified cholinergic vesicles from the electric
organ of the Pacific electric ray Torpedo californica. This
initial cDNA clone (encoding electric-ray -synuclein;
Table 1) was used to isolate a rat clone encoding a 140-
amino-acid protein (rat -synuclein, Table 1). The product of
the -synuclein gene was first isolated as a bovine brain-
specific phosphoprotein (phosphoneuroprotein 14 kDa or
PNP14), and its sequence was first described in 1993 [10]. 
The - and -synuclein proteins are predominately
expressed in brain, particularly in the neocortex, hippocam-
pus, striatum, thalamus, and cerebellum; protein
immunoreactivity is enriched at presynaptic terminals
[11,12]. Although their normal physiological functions are
unknown, several lines of evidence suggest a role in mem-
brane-associated processes at the presynaptic terminal:
-synuclein is specifically upregulated in a discrete popula-
tion of presynaptic terminals of the songbird brain during a
period of song-acquisition-related synaptic rearrangement
[13]; - and -synuclein proteins were biochemically
purified from bovine brain as constitutive inhibitors of phos-
pholipase D2 [14], an enzyme that catalyzes the hydrolysis of
phosphatidylcholine to phosphatidic acid and appears to
play a role in cytoskeletal reorganization and/or endocytosis
at the plasma membrane [15]; -synuclein knockout mice
have enhanced dopamine release at nigrostriatal terminals
in response to paired electrical stimuli, suggesting that
-synuclein is an activity-dependent negative regulator of
dopamine neurotransmission [16]; and, finally, depletion of
-synuclein from cultured primary hippocampal neurons by
treatment with antisense oligonucleotides results in a
decrease in the distal pool of presynaptic vesicles, as visual-
ized by electron microscopy [17]. 
Mammalian -synuclein was first identified as breast cancer-
specific gene 1 (BCSG1) in a high-throughput direct differen-
tial-cDNA-sequencing screen for markers of breast cancer
[18]. The protein is expressed in the peripheral nervous
system (in primary sensory neurons, sympathetic neurons,
and motor neurons) [18] and is also detected in brain [19],
ovarian tumors [20], and in the olfactory epithelium [21]. A
sequence dubbed synoretin was independently isolated from
ocular tissues in a screen for novel proteins regulating pho-
totransduction and is now thought to represent the bovine
ortholog of -synuclein [22]. The normal cellular function of
-synuclein is likewise unknown, but exogenous expression
of the protein increases the invasive and metastatic potential
of breast tumors [23].
Synucleins in neurodegenerative disease
In 1993, Ueda et al. reported [24] that a short peptide (non-
amyloid component, NAC) derived from purified amyloid
Table 1 
Summary of known synuclein family members
Gene type Species Other names OMIM accession number* GenBank accession number†
 Human NACP 163890 586087
 Rat SYN1, SYN2, SYN3 (splice variants) 9507125
 Mouse SYN2 (splice variant) 6678047
 Chicken 7689260
 Canary Synelfin 2501104
 Human 602569 4507111
 Bovine PNP14 464424
 Rat PNP14 2501106
 Mouse 15809030
 Chicken 7689264
 Human BCSG1, persyn 602998 4507113
 Rat Sensory neuron synuclein 13928954
 Mouse Persyn 6755592
 Chicken Persyn 7689262
 Bovine Synoretin 6942174
 Electric ray Synuclein 730882



















plaques from the brains of people with Alzheimer’s disease
was derived from a larger precursor protein, non-amyloid
component precursor (NACP), which is now known to be
identical to human -synuclein. Then, in 1997, Poly-
meropoulos and colleagues reported [25] that a missense
mutation (A53T) in -synuclein was genetically linked to
early-onset, familial Parkinson’s disease. Description of a
second linked mutation (A30P) followed in 1998 [26]. Anti-
bodies to -synuclein protein were used to show that the
protein accumulates in the ubiquitinated protein inclusions
and dystrophic neurites (Lewy bodies and Lewy neurites) that
are the hallmark pathological features of the disease; this
localization was observed even in cases of sporadic Parkin-
son’s disease, which are not associated with -synuclein muta-
tions [27]. Indeed, -synuclein is the primary fibrillar
component of Lewy bodies, and -synuclein lesions are also
observed in cases of dementia with Lewy bodies and multiple
system atrophy, and in some cases of Alzheimer’s disease, the
parkinsonism-dementia complex of Guam, and Hallervorden-
Spatz disease (reviewed in [28]). Although the accumulation
of fibrillar -synuclein in neurodegenerative disease can be
interpreted as evidence that the fibrils are themselves toxic, an
equally plausible view is that the fibrils are inert or even pro-
tective. Conway et al. [29] recently observed that the neuro-
transmitter dopamine forms adducts with -synuclein that
stabilize a protofibrillar form of the protein (at the expense of
fibril formation); the authors proposed that the accumulation
of toxic -synuclein protofibrils could account for the selective
loss of dopamine-containing neurons in Parkinson’s disease.
The detection of -synuclein in ubiquitinated inclusions
raises the issue of whether -synuclein is normally targeted
for turnover by the ubiquitin-proteasome machinery. Although
the evidence for -synuclein turnover by the proteasome is
equivocal [30-32], proteasomal inhibitors do not appear to
cause accumulation of poly-ubiquitinated -synuclein. The
-synuclein binding partner synphilin-1 was, however,
recently shown to be ubiquitinated and targeted for protea-
somal turnover by parkin, a ubiquitin ligase, mutation of
which is itself a risk factor for familial Parkinson’s disease.
This may provide a common pathological mechanism
linking familial mutations in -synuclein and parkin via
their common interactions with synphilin-1 [33]. 
The - and -synuclein proteins are not found in Lewy
bodies, but both are associated with hippocampal axon
pathology in Parkinson’s disease and dementia with Lewy
bodies [34]. A change in the expression of -synuclein has
also been specifically observed in the retina of patients with
Alzheimer’s disease [22].
Figure 1
Alignment and relationships of the 16 known synuclein sequences. There are about 80 synuclein sequences in GenBank [1], which can be further sorted
into 16 unique groups, each representing a single protein-coding sequence orthologous to one of the three synucleins (summarized in Table 1). (a) The
resulting 16 synuclein sequences were aligned with the Multalin program [37]. Shading indicates identity with rat -synuclein;  blue bars represent the 
11-residue repeats. (b) A dendrogram of synuclein relationships, generated with ClustalW [38] and displayed using TreeView [39].
  Rat               MDVFMKGLSKAKEGVVAAAEKTKQGVAEAA-----------GKTKEGVLYVGSKTKEGVVHGVTTVAEKTKEQVTNVGGA
  Mouse             MDVFMKGLSKAKEGVVAAAEKTKQGVAEAA-----------GKTKEGVLYVGSKTKEGVVHGVTTVAEKTKEQVTNVGGA
  Human             MDVFMKGLSKAKEGVVAAAEKTKQGVAEAA-----------GKTKEGVLYVGSKTKEGVVHGVATVAEKTKEQVTNVGGA
  Chicken           MDVFMKGLNKAKEGVVAAAEKTKQGVAEAA-----------GKTKEGVLYVGSRTKEGVVHGVTTVAEKTKEQVSNVGGA
  Canary            MDVFMKGLSKAKEGVVAAAEKTKQGVAEAA-----------GKTKEGVLYVGSRTKEGVVHGVTTVAEKTKEQVSNVGGA
  Rat               MDVFMKGLSMAKEGVVAAAEKTKQGVTEAA-----------EKTKEGVLYVGSKTKEGVVQGVASVAEKTKEQASHLGGA
  Mouse             MDVFMKGLSMAKEGVVAAAEKTKQGVTEAA-----------EKTKEGVLYVGSKT-SGVVQGVASVAEKTKEQASHLGGA
  Human             MDVFMKGLSMAKEGVVAAAEKTKQGVTEAA-----------EKTKEGVLYVGSKTREGVVQGVASVAEKTKEQASHLGGA
  Bovine            MDVFMKGLSMAKEGVVAAAEKTKQGVTEAA-----------EKTKEGVLYVGSKTKEGVVQGVASVAEKTKEQASHLGGA
  Chicken           MEVFMKGLSKAKEGVVAAAEKTKQGVAEAA-----------EKTKEGVLYVGSKT-QGVVQGVTSVAEKAKEQASQLGEA
  Bovine            MDVFKKGFSIAKEGVVGAVEKTKQGVTEAA-----------EKTKEGVMYVGAKTKEGVVQSVTSVAEKTKEQANAVSEA
  Human             MDVFKKGFSIAKEGVVGAVEKTKQGVTEAA-----------EKTKEGVMYVGAKTKENVVQSVTSVAEKTKEQANAVSEA
  Rat               MDVFKKGFSIAREGVVGAVEKTTQGVTEAA-----------EKTKEGVMYVGAKTKGERGTSVTSVAEKTKEQANAVSEA
  Mouse             MDVFKKGFSIAKEGVVGAVEKTKQGVTEAA-----------EKTKEGVMYVGTKTKENVVQSVTSVAEKTKEQANAVSEA
  Chicken           MDVFKKGFSIAKEGVVAAAEKTKQGVTEAA-----------EKTKEGVMYVGTKTKEGVVQSVTSVAEKTKEQANVVGEA
  Electric ray      MDVLKKGFSFAKEGVVAAAEKTKQGVQDAAEKTKQGVQDAAEKTKEGVMYVGTKTKEGVVQSVNTVTEKTKEQANVVGGA
  Rat               VVTGVTAVAQKTVEGAGNIAAATGFVKKDQMGK--GEEGYPQEGILE---DMPVDPSSEAYEMPSEEGYQDYEPEA
  Mouse             VVTGVTAVAQKTVEGAGNIAAATGFVKKDQMGK--GEEGYPQEGILE---DMPVDPGSEAYEMPSEEGYQDYEPEA
  Human             VVTGVTAVAQKTVEGAGSIAAATGFVKKDQLGK--NEEGAPQEGILE---DMPVDPDNEAYEMPSEEGYQDYEPEA
  Chicken           VVTGVTAVAQKTVEGAGNIAAATGLVKKDQLAKQ-NEEGFLQEGMVNN-TDIPVDPENEAYEMPPEEEYQDYEPEA
  Canary            VVTGVTAVAQKTVEGAGNIAAATGLVKKDQLAKQ-NEEGFLQEGMVNN-TGAAVDPDNEAYEMPPEEEYQDYEPEA
  Rat               VFS-----------GAGNIAAATGLVKKEEFPTDLKPEEVAQEAAEEPLIEPLMEPEGESYEDSPQEEYQEYEPEAKGP
  Mouse             VFS-----------GAGNIAAATGLVKKEEFPTDLKPEEVAQEAAEEPLIEPLMEPEGESYEDSPQEEYQEYEPEA
  Human             VFS-----------GAGNIAAATGLVKREEFPTDLKPEEVAQEAAEEPLIEPLMEPEGESYEDPPQEEYQEYEPEA
  Bovine            VFS-----------GAGNIAAATGLVKKEEFPTDLKPEEVAQEAAEEPLIEPLMEPEGESYEEQPQEEYQEYEPEA
  Chicken           AFS-----------GAGNIAAATGLVKKEEFPADLKAEEVAQEAVEEPLVEPLLEPEGESYEESPQEEYQEYEPEA
  Bovine            VVSSVNTVATKTVEEVENIAVTSGVVHKEALKQPVPSQED--------------EAAKA-EEQVAEETKSGGD
  Human             VVSSVNTVATKTVEEAENIAVTSGVVRKEDLRPSAPQQEG--------------VASKE-KEEVAEEAQSGGD
  Rat               VVSSVNTVATETVEEAENIVVTTGVVRKEDLEPPAQDQE-----------------AKE-QEE-GEEAKSGGD
  Mouse             VVSSVNTVANKTVEEAENIVVTTGVVRKEDLEPPAQDQE-----------------AKE-QEE-NEEAKSGED
  Chicken           VVASVNTVANKTVEGAETIVATTGVVKKEDLAPQQPAAEG--------------EAAIPGSTEGGGEGENEGN



















































The association of synucleins with human disease has focused
a great deal of interest on this protein family. The question of
what the synucleins do still remains, however. Most of the
experimental evidence available with regard to function is
gleaned from experiments with -synuclein, but the conser-
vation of an extended, class-A2 amphipathic  helix compris-
ing more than half of each of the protein sequences indicates
a common biochemical mechanism among all synucleins,
probably involving lipid binding. Perrin et al. [35] report irre-
versible multimerization of -, -, and -synuclein upon
exposure to polyunsaturated phospholipid species, cellular
membrane components that are the most susceptible to
oxidative damage. This specific interaction might serve to
protect these vulnerable lipids from damage or to scavenge
damaged lipids and target them for turnover. Paxinou et al.
[32] also noted recently that -synuclein is degraded, at least
in part, by the lysosome, suggesting a role for -synuclein in
the autophagocytic clearance of damaged cellular organelles.
Thus, it is tempting to speculate that the synucleins help to
maintain cellular membrane integrity. But much work
remains to be done to elucidate the normal cellular functions
of these unusually conserved proteins and to determine how
they contribute to diverse disease processes spanning neuro-
degenerative disease and cancer.
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